Alterity Therapeutics Ltd. Sponsored ADR Stock

$5.58

14.81% yesterday

Nasdaq, Jul 28, 10:17 pm CET

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Alterity Therapeutics Ltd. Sponsored ADR Stock price

$5.58

-9.02 61.78% 5Y

Nasdaq, Closing price Mon, Jul 28 2025

-0.97 14.81%

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$90.7m

Enterprise Value

$87.8m

Net debt

positive

Cash

$3.0m

Shares outstanding

5.3b

Valuation (TTM | estimate)

P/E

- | negative

P/S

533.5 | 63.8

EV/Sales

516.4 | 61.2

EV/FCF

P/B

17.8

Financial Health

Equity Ratio

Return on Equity

ROCE

-254.3%

ROIC

-596.6%

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$170.0k | $1.1m

EBITDA

$-13.0m | -

EBIT

$-13.1m | -

Net Income

$-13.0m | $-4.4b

Free Cash Flow

Growth (TTM | estimate)

Revenue

112.5% | 520.0%

EBITDA

-39.9% | -

EBIT

-39.7% | -

Net Income

-61.1% | -34,634.7%

Free Cash Flow

EPS

$0.0

FCF per Share

Short interest

1.1%

Employees

Rev per Employee

$20.0k

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Get Started for Free Today

Alterity Therapeutics Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

Financial data from Alterity Therapeutics Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.17 0.17	113% 113% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.75 3.75	31% 31% 2,206%
- Research and Development Expense	12 12	53% 53% 6,953%
EBITDA	-13 -13	40% 40% -7,647%
- Depreciation and Amortization	0.10 0.10	25% 25% 59%
EBIT (Operating Income) EBIT	-13 -13	40% 40% -7,703%
Net Profit	-13 -13	61% 61% -7,647%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Alterity Therapeutics Ltd. Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

about 14 hours ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms –

Neutral

GlobeNewsWire

●

5 days ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy –

Neutral

GlobeNewsWire

●

about one month ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access ...

More Alterity Therapeutics Ltd. Sponsored ADR News

Company Profile

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Head office	Australia
CEO	Dr. Stamler
Employees	10
Founded	1997
Website	alteritytherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now